75歳の人口における心房細動の段階的なスクリーニング:脳卒中予防への影響
Johan Engdahl1, Lisbeth Andersson, Maria Mirskaya
1Department of Medicine, Hallands Hospital Halmstad, Sweden. johan.engdahl@regionhalland.se
Circulation
|January 25, 2013
まとめ
75歳児における未診断の心房細動 (AF) のスクリーニングでは,抗凝固薬を必要とする人が9%であることが判明しました. この段階的なアプローチは,脳卒中予防治療の候補者を効果的に見つけます.
科学分野:
- 心臓病学 心臓病学
- 公衆衛生は公衆衛生である.
- ゲリアトリクス ゲリアトリクス
背景:
- 心房細動 (AF) は,心臓栓塞による脳卒中の一般的な原因です.
- 診断されていないAFは,しばしば無症状であるため,重大なリスクをもたらす.
- リスク集団における静かなAFのスクリーニングは論理的だが,収量と費用対効果に関するデータは欠けている.
研究 の 目的:
- 高齢者におけるAFの段階的なスクリーニングプログラムの成果を評価する.
- 経口抗凝固療法のための候補者を特定するために.
主な方法:
- スウェーデンのハルムスタッドで75~76歳の人々に対して段階的なスクリーニングプログラムが実施されました.
- 参加者は12点のECGとリスクファクター評価を受けていました.
- AFが診断されていないが,リスク要因のある個人は,2週間,手持式心電図を使用した.
主要な成果:
- 848人の参加者のうち,10人 (1%) は,以前に診断されていない静かなAFを12リードEKGで検出していました.
- 危険因子のある患者では,30人 (7.4%) が手持式心電図を用いて,心筋梗塞性AFと診断されました.
- 全体として,75人の参加者 (9%) が口服抗凝固薬の候補者として特定されました.
結論:
- 75歳におけるAFの段階的,リスク分層のスクリーニングは効果的です.
- スクリーニングにより,経口抗凝固療法に適した多数の個人が特定され,脳卒中予防に役立ちます.
関連する概念動画
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


